Please use this identifier to cite or link to this item:
https://hdl.handle.net/10216/149551Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | Brandão, M | |
| dc.creator | Guisseve, A | |
| dc.creator | Bata, G | |
| dc.creator | Firmino-Machado, J | |
| dc.creator | Alberto, M | |
| dc.creator | Ferro, J | |
| dc.creator | Garcia, C | |
| dc.creator | Zaqueu, C | |
| dc.creator | Jamisse, A | |
| dc.creator | Lorenzoni, C | |
| dc.creator | Piccart-Gebhart, M | |
| dc.creator | Leitão, D | |
| dc.creator | Come, J | |
| dc.creator | Soares, O | |
| dc.creator | Gudo-Morais, A | |
| dc.creator | Schmitt, F | |
| dc.creator | Tulsidás, S | |
| dc.creator | Carrilho, C | |
| dc.creator | Lunet, N | |
| dc.date.accessioned | 2023-05-23T14:23:51Z | - |
| dc.date.available | 2023-05-23T14:23:51Z | - |
| dc.date.issued | 2021 | |
| dc.identifier.issn | 1083-7159 | |
| dc.identifier.issn | 1549-490X | |
| dc.identifier.uri | https://hdl.handle.net/10216/149551 | - |
| dc.description.abstract | Background Despite the international endorsement of multidisciplinary tumor boards (MTBs) for breast cancer care, implementation is suboptimal worldwide, and evidence regarding their effectiveness in developing countries is lacking. We assessed the impact on survival and the cost-effectiveness of implementing an MTB in Mozambique, sub-Saharan Africa. Materials and Methods This prospective cohort study included 205 patients with breast cancer diagnosed between January 2015 and August 2017 (98 before and 107 after MTB implementation), followed to November 2019. Pre- and post-MTB implementation subcohorts were compared for clinical characteristics, treatments, and overall survival. We used hazard ratios and 95% confidence intervals (CI), computed by Cox proportional hazards regression. The impact of MTB implementation on the cost per quality-adjusted life year (QALY) was estimated from the provider perspective. Results We found no significant differences between pre- and post-MTB subcohorts regarding clinical characteristics or treatments received. Among patients with early breast cancer (stage 0–III; n = 163), the 3-year overall survival was 48.0% (95% CI, 35.9–59.1) in the pre-MTB and 73.0% (95% CI, 61.3–81.6) in the post-MTB subcohort; adjusted hazard ratio, 0.47 (95% CI, 0.27–0.81). The absolute 3-year mean cost increase was $119.83 per patient, and the incremental cost-effectiveness ratio was $802.96 per QALY, corresponding to 1.6 times the gross domestic product of Mozambique. Conclusion The implementation of a MTB in Mozambique led to a 53% mortality decrease among patients with early breast cancer, and it was cost-effective. These findings highlight the feasibility of implementing this strategy and the need for scaling-up MTBs in developing countries, as a way to improve patient outcomes. Implications for Practice Currently, more than half of the deaths from breast cancer in the world occur in developing countries. Strategies that optimize care and that are adjusted for available resources are needed to improve the outcomes of patients with breast cancer in these regions. The discussion of cases at multidisciplinary tumor boards (MTBs) may improve survival outcomes, but implementation is suboptimal worldwide, and evidence regarding their effectiveness in developing countries is lacking. This study evaluated the impact of implementing an MTB on the care and survival of patients with breast cancer in Mozambique, sub-Saharan Africa and its cost-effectiveness in this low-income setting. | |
| dc.description.sponsorship | The Calouste Gulbenkian Foundation supported the training of professionals (J.C., A.J., A.G.) in breast cancer care at the Centro Hospitalar Universitário de São João, under the Project “Atenção Integrada ao Doente Oncológico.” We posthumously thank Dr. João Fumane, former head of the Oncology Unit (2000–2011) and Director of the Maputo Central Hospital (from 2012 until his death, in 2017), for his continuous support to this cohort study. We thank Dr. Samantha Morais, from the Instituto de Saúde Pública, Universidade do Porto, for proof-reading the manuscript. This study was approved by the National Health Bioethical Committee of Mozambique (reference number 226/CNBS/15). All participants provided written informed consent. This study was performed in accordance with the Declaration of Helsinki. The Moza-BC cohort study was supported by the Beginning Investigator Grant for Catalytic Research (BIG Cat) program, an African Organisation for Research and Training in Cancer program with support from the U.S. National Cancer Institute (grant number 59–210–6-004). The funding source had no role in the study design, in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. | |
| dc.language.iso | eng | |
| dc.publisher | Oxford University Press | |
| dc.relation.ispartof | Oncologist. 2021 Jun;26(6):e996-e1008 | |
| dc.rights | openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Breast neoplasms | |
| dc.subject | Sub-Saharan Africa | |
| dc.subject | Developing countries | |
| dc.subject | Survival analysis | |
| dc.subject | Cost-effectiveness analysis | |
| dc.title | Survival Impact and Cost-Effectiveness of a Multidisciplinary Tumor Board for Breast Cancer in Mozambique, Sub-Saharan Africa | |
| dc.type | Artigo em Revista Científica Internacional | |
| dc.contributor.uporto | Instituto de Saúde Pública da Universidade do Porto | |
| dc.identifier.doi | 10.1002/onco.13643 | |
| dc.relation.publisherversion | https://academic.oup.com/oncolo/article/26/6/e996/6520942 | |
| Appears in Collections: | ISPUP - Artigo em Revista Científica Internacional | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| brandao-to-2021.pdf | 11.46 MB | Adobe PDF | ![]() View/Open |
This item is licensed under a Creative Commons License
